*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not, and is not intended to, constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States or in any other jurisdictions. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933 as amended from time to time (the "**U.S. Securities Act**") or securities law of any state or other jurisdiction of the United States. The securities may not be offered, sold, pledged or otherwise transferred within the United States except in transactions exempt from, or not subject to, the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws. There will be no public offer of securities in the United States. The securities are being offered and sold solely outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act and applicable laws of each jurisdiction where those offers and sales occur.*

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities. Any investment decision in relation to the Offer Shares should be taken solely in reliance on the information in the Prospectus. The Company has not been and will not be registered under the U.S. Investment Company Act of 1940, as amended.

*Unless otherwise defined in this announcement, capitalized terms used herein shall have the same meanings as those defined in the prospectus dated January 29, 2026 (the "**Prospectus**") issued by Distinct Healthcare Holdings Limited (卓正医疗控股有限公司) (the "**Company**").*

This announcement is made pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong).

卓正医疗
Distinct HealthCare

Distinct Healthcare Holdings Limited
卓正医疗控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2677)

PARTIAL EXERCISE OF THE OVER-ALLOTMENT OPTION, STABILIZING ACTIONS AND END OF STABILIZATION PERIOD

PARTIAL EXERCISE OF THE OVER-ALLOTMENT OPTION

The Company announces that the Over-allotment Option described in the Prospectus has been partially exercised by the Joint Sponsor-Overall Coordinators (for themselves and on behalf of the International Underwriters), on Thursday, March 5, 2026, in respect of an aggregate of 196,100 Shares (the "**Over-allotment Shares**"), representing approximately 4.13% of the total number of the Offer Shares available under the Global Offering before any exercise of the Over-allotment Option.

The Over-allotment Shares will be issued and allotted by the Company at HK$59.90 per Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027%, the Stock Exchange trading fee of 0.00565% and AFRC transaction levy of 0.00015%), being the final Offer Price per Share under the Global Offering. The Over-allotment Shares will be used to facilitate the delivery of part of Shares to the investor who has agreed to delayed delivery of the relevant Offer Shares subscribed by them under the Global Offering.

STABILIZING ACTIONS AND END OF STABILIZATION PERIOD

Pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong), the Company announces that the stabilization period in connection with the Global Offering ended on Thursday, March 5, 2026, being the 30th day after the last day for lodging applications under the Hong Kong Public Offering. Further information on the stabilizing actions undertaken by Haitong International Securities Company Limited, the Stabilization Manager, or its affiliates or any person acting for it, during the stabilization period is set out in this announcement.

PARTIAL EXERCISE OF THE OVER-ALLOTMENT OPTION

Pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong), the Company announces that the Over-allotment Option described in the Prospectus has been partially exercised by the Joint Sponsor-Overall Coordinators (for themselves and on behalf of the International Underwriters), on Thursday, March 5, 2026, in respect of an aggregate of 196,100 Shares, representing approximately 4.13% of the total number of the Offer Shares available under the Global Offering before any exercise of the Over-allotment Option.

The Over-allotment Shares will be issued and allotted by the Company at HK$59.90 per Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027%, the Stock Exchange trading fee of 0.00565% and AFRC transaction levy of 0.00015%), being the final Offer Price per Share under the Global Offering. The Over-allotment Shares will be used to facilitate the delivery of part of Shares to the investor who has agreed to delayed delivery of the relevant Offer Shares subscribed by them under the Global Offering.

Approval of Listing

Approval for the listing of and permission to deal in the Over-allotment Shares has already been granted by the Stock Exchange. Listing of and dealings in the Over-allotment Shares are expected to commence on the Main Board of the Stock Exchange at 9:00 a.m. on Tuesday, March 10, 2026.

Shareholding Structure of the Company upon the Completion of the Partial Exercise of the Over-allotment Option

The shareholding structure of the Company immediately before and immediately after the completion of the partial exercise of the Over-allotment Option is as follows:

	Immediately before the completion of the partial exercise of the Over-allotment Option		Immediately after the completion of the partial exercise of the Over-allotment Option	
Shareholders	*Number of Shares*	*Approximate % of the Company's total share capital*	*Number of Shares*	*Approximate % of the Company's total share capital*
Non-public Shareholders				
Controlling Shareholders				
Cheuk Sing Ho	11,283,000	17.52%	11,283,000	17.47%
Distinct Partners I Limited	2,640,250	4.10%	2,640,250	4.09%
Mr. CAO Shaoshan	1,000,000	1.55%	1,000,000	1.55%
Nineteen Seventy-Seven	867,000	1.35%	867,000	1.34%
Proxy Shares held by H Capital IV, L.P.	1,597,048	2.48%	1,597,048	2.47%
Proxy Shares held by Image Frame Investment (HK) Limited	2,079,683	3.23%	2,079,683	3.22%
Proxy Shares held by MPC II L.P.	319,096	0.50%	319,096	0.49%
Proxy Shares held by MPC II-A L.P.	35,455	0.06%	35,455	0.05%
Other Shareholders				
Image Frame Investment (HK) Limited(1)	9,486,369	14.73%	9,486,369	14.69%
H Capital IV, L.P.(2)	7,284,852	11.31%	7,284,852	11.28%
Waterwood DHC Project Ltd	7,500,000	11.65%	7,500,000	11.61%
Waterwood Tactics Limited	989,810	1.54%	989,810	1.53%
Sub-total	45,082,563	70.02%	45,082,563	69.81%
Public Shareholders				
Cornerstone investors				
Health Vision Hong Kong Limited	727,200	1.13%	727,200	1.13%
KingMed Diagnostics (Hong Kong) Limited (金域檢驗(香港)有限公司)	386,600	0.60%	386,600	0.60%
Mininglamp Technology	257,750	0.40%	257,750	0.40%
Galaxy Dynasty Limited	128,850	0.20%	128,850	0.20%
Other public Shareholders(3)	17,801,387	27.65%	17,997,487	27.87%
Sub-total	19,301,787	29.98%	19,497,887	30.19%
Total	**64,384,350**	**100.00%**	**64,580,450**	**100.00%**

Notes:

(1) Exclusive of the 2,079,683 Proxy Shares held by Image Frame Investment (HK) Limited.

(2) Exclusive of the 1,597,048 Proxy Shares held by H Capital IV, L.P..

(3) Exclusive of the 319,096 Proxy Shares held by MPC II, L.P. and the 35,455 Proxy Shares held by MPC II-A, L.P..

Use of Proceeds

The Company will receive additional net proceeds of approximately HK$11.28 million from the issue of the Over-allotment Shares, after deduction of underwriting fees and commissions and estimated expenses payable by the Company in connection with the partial exercise of the Over-allotment Option. The Company intends to utilize the additional net proceeds on a pro rata basis for the purposes as set out in the section headed "Future Plans and Use of Proceeds" in the Prospectus.

STABILIZING ACTIONS AND END OF STABILIZATION PERIOD

Pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong), the Company announces that the stabilization period in connection with the Global Offering ended on Thursday, March 5, 2026, being the 30th day after the last day for lodging applications under the Hong Kong Public Offering. The stabilizing actions undertaken by Haitong International Securities Company Limited, or its affiliates or any person acting for it, during the stabilization period are set out below:

(1) over-allocations of an aggregate of 712,500 Shares in the International Offering, representing 15% of the total number of Offer Shares available under the Global Offering before any exercise of the Over-allotment Option;

(2) successive purchases of an aggregate of 516,400 Shares in the price range of HK$53.20 to HK$59.90 per Share (excluding brokerage of 1.0%, SFC transaction levy of 0.0027%, AFRC transaction levy of 0.00015% and Stock Exchange trading fee of 0.00565%) on the market during the stabilization period, representing approximately 10.87% of the total number of the Offer Shares available under the Global Offering before any exercise of the Over-allotment Option. The last purchase made by the Stabilization Manager or its affiliates or any person acting for it, on the market during the course of the stabilization period was on Thursday, March 5, 2026 at the price of HK$59.90 per Share (excluding brokerage of 1.0%, SFC transaction levy of 0.0027%, AFRC transaction levy of 0.00015% and Stock Exchange trading fee of 0.00565%); and

(3) the partial exercise of the Over-allotment Option by the Joint Sponsor-Overall Coordinators (for themselves and on behalf of the International Underwriters), on Thursday, March 5, 2026, in respect of an aggregate of 196,100 Shares, at HK$59.90 per Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027%, the Stock Exchange trading fee of 0.00565% and AFRC transaction levy of 0.00015%), being the final Offer Price per Share under the Global Offering, to facilitate the delivery of part of Shares to the investor who has agreed to delayed delivery of the relevant Offer Shares subscribed by them under the Global Offering.

The portion of the Over-allotment Option which has not been exercised by the Joint Sponsor-Overall Coordinators for themselves and on behalf of the International Underwriters lapsed on Thursday, March 5, 2026.

PUBLIC FLOAT

Immediately after the partial exercise of the Over-allotment Option and the end of the stabilization period, the Company will continue to comply with the public float requirements under Rule 8.08(1) of the Listing Rules.

By order of the Board
Distinct Healthcare Holdings Limited
卓正医疗控股有限公司
WANG Zhiyuan
Chairman and Executive Director

Hong Kong, March 5, 2026

As of the date of this announcement, the Board comprises Mr. WANG Zhiyuan and Mr. SHI Yi as executive Directors, Mr. CAO Shaoshan, Mr. ZHANG Xiangdong, Mr. WEI Guoxing, Ms. CHEN Xiaohong and Mr. HAO Rui as non-executive Directors, and Ms. CHEN Rui, Mr. WANG Yonggang, Mr. WANG Gaofei and Dr. GAO Pingyang as independent non-executive Directors.